COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Compression Device Safety Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00732823
Recruitment Status : Completed
First Posted : August 12, 2008
Last Update Posted : October 31, 2008
Bristol-Myers Squibb
Information provided by:
ConvaTec Inc.

Brief Summary:
To evaluate the safety of the Compression Device to subjects with venous insufficiency and oedema.

Condition or disease Intervention/treatment Phase
Venous Insufficiency Device: Placebo - No device worn Device: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase II Randomized Study to Evaluate the Safety of the Compression Test Device Using Intermittent Pneumatic Compression Mode in Subjects With Venous Insufficiency and Oedema
Study Start Date : July 2005
Actual Primary Completion Date : October 2005
Actual Study Completion Date : October 2005

Arm Intervention/treatment
Placebo Comparator: Profile A
No device worn
Device: Placebo - No device worn
Active Comparator: Profile B
Foot 40 mmHg, ankle 40 mmHg, mid-calf 35 mmHg, upper calf 30 mmHg
Device: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Active Comparator: Profile C
Foot 50 mmHg, ankle 50 mmHg, mid-calf 45 mmHg, upper calf 40 mmHg
Device: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Active Comparator: Profile D
Foot 60 mmHg, ankle 60 mmHg, mid-calf 55 mmHg, upper calf 50 mmHg
Device: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs

Primary Outcome Measures :
  1. The nature and frequency of adverse events
  2. Distal arterial flow

Secondary Outcome Measures :
  1. Volume reduction will be measured by recording limb volume at the start and end of each profile for both legs. The test leg will be compared to baseline and the contralateral leg. Comfort during wear will be recorded on completion of each profile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects over 18 years, willing and able to provide written informed consent.
  • Subjects able to wear the Amadeus device and follow the requirements of the clinical investigation plan
  • Subjects who have an ankle to brachial pressure index (ABPI) of ABPI >0.8
  • Subjects with chronic lower limb oedema (i.e. CEAP classification of C3, C4 or C5 1.)
  • Subjects who have Chronic Venous Insufficiency (CVI), which has been present for 6 weeks or longer and who have refluxes >0.5 sec in one or more major venous segments, superficial or deep or both (CEAP classification: C3-C5 1.; Ep,s; As,d; Pr).

Exclusion Criteria:

  • Subjects with a history of skin sensitivity to any of the components of the study product.
  • Subjects who have previously been entered into the study before
  • Subjects who have a history of Deep Vein Thrombosis (DVT) within the last 6 months
  • Subjects who have an active leg ulcer (i.e. CEAP classification of C6 1).
  • Subjects with active cardiac disease or significant history of cardiac disease (including history of myocardial infarction, heart failure, valvular disease, arrhythmia and those with a pacemaker or have previously had a pacemaker).
  • Subjects who have initiated treatment or changed the dose within the past month of pharmaceutical agents that reduce clotting e.g. aspirin (except low-dose aspirin), anti-platelets, anti-coagulants and coumarin.
  • Subjects who are currently taking pharmaceutical agents that can modify the amount of leg oedema (e.g., diuretics, dihydropyridine calcium channel blockers, phlebotonic drugs, or fluctuating doses of systemic steroids) or have taken these agents within the last 10 days.
  • Subjects who are pregnant
  • Subjects who have worn compression therapy in the last 48 hours
  • Subjects who have leg sizes outside the following range:

    • Ankle 17cm - 32cm
    • Calf 27cm - 47cm
    • Below Knee 29cm - 51cm

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00732823

Layout table for location information
Hautarzt Phlebologe Allergologe
Freiburg, Germany
Sponsors and Collaborators
ConvaTec Inc.
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: wolfgang Vanscheidt Facharzt für Dermatologie Phlebologie Allergologie
Layout table for additonal information
Responsible Party: Professor Dr. med Wolfgang Vanscheidt, Hautarzt Phlebologe Allergologe Identifier: NCT00732823    
Other Study ID Numbers: CW-0500-05-U337
First Posted: August 12, 2008    Key Record Dates
Last Update Posted: October 31, 2008
Last Verified: August 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Venous Insufficiency
Vascular Diseases
Cardiovascular Diseases